Treatment of Spontaneous Bacterial Peritonitis

  • Hiroko Setoyama
  • Motohiko Tanaka
  • Yutaka SasakiEmail author


After the diagnosis of spontaneous bacterial peritonitis (SBP), patients should immediately receive empiric antibiotic treatment. Until the results of susceptibility testing are available, broad-spectrum therapy is warranted in patients with a suspected ascitic fluid infection. A reasonable choice for suspected SBP is a third-generation cephalosporin, preferably cefotaxime 2 g every 8 h. In uncomplicated SBP, oral ofloxacin (400 mg twice per day for an average of 8 days) also provides similar results as intravenous cefotaxime. Intravenous albumin infusions can also decrease the risk of renal impairment that often develops in patients with SBP. Several randomized controlled trials have reported that the administration of antibiotic prophylaxis in high-risk SBP patients can decrease the risk of bacterial infection and mortality. However, in order to minimize bacterial resistance, it is necessary to restrict the use of these prophylactic antibiotics to patients who demonstrate the well-defined criteria for SBP prophylaxis.


Empirical antibiotic therapy Cefotaxime Intravenous albumin infusion Prophylactic regimen Norfloxacin Bacterial resistance 


  1. 1.
    Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. Int Ascites Club J Hepatol. 2000;32:142–53.Google Scholar
  2. 2.
    Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon. 1985;31:1–48.CrossRefGoogle Scholar
  3. 3.
    Hoefs JC, Canawati HN, Sapico FL, Hopkins RR, Weiner J, Montgomerie JZ. Spontaneous bacterial peritonitis. Hepatology. 1982;2:399–407.CrossRefGoogle Scholar
  4. 4.
    Such J, Runyon BA. Spontaneous bacterial peritonitis. Clin Infect Dis. 1998;27:669–74. quiz 675-666CrossRefGoogle Scholar
  5. 5.
    Chavez-Tapia NC, Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. Cochrane Database Syst Rev. 2009:CD002232.Google Scholar
  6. 6.
    Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology. 1985;5:457–62.CrossRefGoogle Scholar
  7. 7.
    Runyon BA, Akriviadis EA, Sattler FR, Cohen J. Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis. Dig Dis Sci. 1991;36:1782–6.CrossRefGoogle Scholar
  8. 8.
    Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49:2087–107.CrossRefGoogle Scholar
  9. 9.
    Rimola A, Salmeron JM, Clemente G, Rodrigo L, Obrador A, Miranda ML, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology. 1995;21:674–9.CrossRefGoogle Scholar
  10. 10.
    Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short-course versus long-course antibiotic treatment of spontaneous bacterial peritonitis. A randomized controlled study of 100 patients. Gastroenterology. 1991;100:1737–42.CrossRefGoogle Scholar
  11. 11.
    EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.Google Scholar
  12. 12.
    Ricart E, Soriano G, Novella MT, Ortiz J, Sabat M, Kolle L, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000;32:596–602.CrossRefGoogle Scholar
  13. 13.
    Navasa M, Follo A, Llovet JM, Clemente G, Vargas V, Rimola A, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111:1011–7.CrossRefGoogle Scholar
  14. 14.
    Jalan R, Fernandez J, Wiest R, Schnabl B, Moreau R, Angeli P, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol. 2014;60:1310–24.CrossRefGoogle Scholar
  15. 15.
    Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology. 1994;20:1495–501.CrossRefGoogle Scholar
  16. 16.
    Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–9.CrossRefGoogle Scholar
  17. 17.
    Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M. Restricted use of albumin for spontaneous bacterial peritonitis. Gut. 2007;56:597–9.CrossRefGoogle Scholar
  18. 18.
    Fernandez J, Monteagudo J, Bargallo X, Jimenez W, Bosch J, Arroyo V, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology. 2005;42:627–34.CrossRefGoogle Scholar
  19. 19.
    Setoyama H, Tanaka M, Nagumo K, Naoe H, Watanabe T, Yoshimaru Y, et al. Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients. J Gastroenterol. 2017;52(6):754–65.CrossRefGoogle Scholar
  20. 20.
    Runyon BA. Low-protein-concentration ascitic fluid is predisposed to spontaneous bacterial peritonitis. Gastroenterology. 1986;91:1343–6.CrossRefGoogle Scholar
  21. 21.
    Bleichner G, Boulanger R, Squara P, Sollet JP, Parent A. Frequency of infections in cirrhotic patients presenting with acute gastrointestinal haemorrhage. Br J Surg. 1986;73:724–6.CrossRefGoogle Scholar
  22. 22.
    Bernard B, Cadranel JF, Valla D, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology. 1995;108:1828–34.CrossRefGoogle Scholar
  23. 23.
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology. 2001;120:726–48.CrossRefGoogle Scholar
  24. 24.
    Soriano G, Guarner C, Teixido M, Such J, Barrios J, Enriquez J, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology. 1991;100:477–81.CrossRefGoogle Scholar
  25. 25.
    Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology. 1990;12:716–24.CrossRefGoogle Scholar
  26. 26.
    Soriano G, Guarner C, Tomas A, Villanueva C, Torras X, Gonzalez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992;103:1267–72.CrossRefGoogle Scholar
  27. 27.
    Blaise M, Pateron D, Trinchet JC, Levacher S, Beaugrand M, Pourriat JL. Systemic antibiotic therapy prevents bacterial infection in cirrhotic patients with gastrointestinal hemorrhage. Hepatology. 1994;20:34–8.CrossRefGoogle Scholar
  28. 28.
    Fernandez J, Ruiz del Arbol L, Gomez C, Durandez R, Serradilla R, Guarner C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131:1049–56; quiz 1285.CrossRefGoogle Scholar
  29. 29.
    Singh N, Gayowski T, Yu VL, Wagener MM. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med. 1995;122:595–8.CrossRefGoogle Scholar
  30. 30.
    Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57:1651–3.CrossRefGoogle Scholar
  31. 31.
    Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Dig Dis. 2016;34:382–6.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Hiroko Setoyama
    • 1
  • Motohiko Tanaka
    • 1
  • Yutaka Sasaki
    • 1
    Email author
  1. 1.Department of Gastroenterology and HepatologyGraduate School of Medical Sciences, Kumamoto UniversityKumamotoJapan

Personalised recommendations